Brief: Advicenne: 1st Patient Enrolled In US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 In dRTA

Advicenne SA

29/08/2019 17:14

Aug 29 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * ADVICENNE ANNOUNCES FIRST PATIENT ENROLLED IN US ARENA-2 PIVOTAL PHASE III CLINICAL TRIAL
EVALUATING ADV7103 IN DISTAL RENAL TUBULAR ACIDOSIS (DRTA)
    * ARENA-2 TRIAL IS EXPECTED TO INCLUDE APPROXIMATELY 40 PATIENTS
    * ADVICENNE HAS ALSO FILED AN APPLICATION FOR ORPHAN DRUG DESIGNATION (ODD) FOR ADV7103 IN
UNITED
STATES
    * ARENA-2: 8 STUDY CENTERS ARE ALREADY OPEN AND RESULTS ARE EXPECTED IN BEGINNING OF 2021
    * PRESENT STUDY WAS INITIATED FOLLOWING A EUROPEAN ARENA-1 CLINICAL TRIAL THAT DEMONSTRATED
POSITIVE RESULTS AFTER 24 MONTHS OF TREATMENT

Source text for Eikon:  ID:nBw9bHyKxa 
Further company coverage:  ADVIC.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))